Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALKS 2680 in adults with narcolepsy type 1
2025-524711-36-00Phase 3Authorised
- Sponsor
- Alkermes
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in narcolepsy type 1 (NT1) comparing ALKS 2680 dose arm(s) with Placebo arm (2 arms). Primary endpoint: Change in Epworth Sleepiness Scale from baseline to Week 12 by dose level. Planned start Aug 2026; status: authorised.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on 2025-524711-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524711-36-00.